These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 571916)

  • 1. Mapping the dopamine receptor. 1. Features derived from modifications in ring E of the neuroleptic butaclamol.
    Humber LG; Bruderlein FT; Philipp AH; Götz M
    J Med Chem; 1979 Jul; 22(7):761-7. PubMed ID: 571916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping the dopamine receptor. 2. Features derived from modifications in the rings A/B region of the neuroleptic butaclamol.
    Philipp AH; Humber LG; Voith K
    J Med Chem; 1979 Jul; 22(7):768-73. PubMed ID: 571917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroleptics related to butaclamol. An investigation of the effects of chlorine substituents on the aromatic rings.
    Humber LG; Sideridis N; Asselin AA; Bruderlein FT; Voith K
    J Med Chem; 1978 Dec; 21(12):1225-31. PubMed ID: 31480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroleptics related to butaclamol. Synthesis and some psychopharmacological effects of a series of 3-aryl analogues.
    Voith K; Bruderlein FT; Humber LG
    J Med Chem; 1978 Jul; 21(7):694-8. PubMed ID: 27637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of the butaclamol template in a search for antipsychotic agents with lessened side effects.
    Kukla MJ; Bloss JL; Brougham LR
    J Med Chem; 1979 Apr; 22(4):401-6. PubMed ID: 34721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopaminergic activity of four analogs of butaclamol.
    Collu R; Bouvier C; Basak A; Dugas H
    Pharmacol Res Commun; 1985 Dec; 17(12):1153-7. PubMed ID: 2419927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The behavioral pharmacology of butaclamol hydrochloride (AY-23,028), a new potent neuroleptic drug.
    Voith K; Herr F
    Psychopharmacologia; 1975 Apr; 42(1):11-20. PubMed ID: 1171496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pKa of butaclamol and the mode of butaclamol binding to central dopamine receptors.
    Chrzanowski FA; McGrogan BA; Maryanoff BE
    J Med Chem; 1985 Mar; 28(3):399-400. PubMed ID: 2579238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [3H]dihydroergocryptine binding to bovine striatal membranes defined by a low d-butaclamol concentration: antagonism by substituted benzamides.
    Lin CW; Maayani S; Wilk S
    Biochem Pharmacol; 1981 Jun; 30(11):1305-14. PubMed ID: 6168265
    [No Abstract]   [Full Text] [Related]  

  • 10. Behavioral studies on the enantiomers of butaclamol demonstrating absolute optical specificity for neuroleptic activity.
    Voith K; Cummings JR
    Can J Physiol Pharmacol; 1976 Aug; 54(4):551-60. PubMed ID: 10059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroleptic receptors: stereoselectivity for neuroleptic enantiomers.
    Seeman P; Westman K; Protiva M; Jílek J; Jain PC; Saxena AK; Anand N; Humber L; Philipp A
    Eur J Pharmacol; 1979 Jun; 56(3):247-51. PubMed ID: 38971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buspirone: chemical profile of a new class of anxioselective agents.
    Temple DL; Yevich JP; New JS
    J Clin Psychiatry; 1982 Dec; 43(12 Pt 2):4-10. PubMed ID: 6185470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of chlorine substituents on the benzene rings of an analogue of the antipsychotic drug butaclamol on the interaction with dopamine and muscarinic receptors in rat brain.
    Pugsley TA; Lippmann W
    J Pharm Pharmacol; 1979 Jan; 31(1):47-9. PubMed ID: 32368
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect of the stereoisomers of butaclamol on neurotensin content in discrete regions of the rat brain.
    Bissette G; Dauer WT; Kilts CD; O'Connor L; Nemeroff CB
    Neuropsychopharmacology; 1988 Dec; 1(4):329-35. PubMed ID: 2472151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulsatile growth hormone and prolactin: effects of (+) butaclamol, a dopamine receptor blocking agent.
    Willoughby JO; Brazeau P; Martin JB
    Endocrinology; 1977 Oct; 101(4):1298-303. PubMed ID: 908278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of butaclamol enantiomers on hypothalamic tyrosine hydroxylase in the rat brain].
    Mineeva MF; Raevskiĭ KS
    Biull Eksp Biol Med; 1984 Oct; 98(10):453-6. PubMed ID: 6208950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prenatal neuroleptic exposure alters postnatal striatal cholinergic activity in the rat.
    Miller JC; Friedhoff AJ
    Dev Neurosci; 1986; 8(2):111-6. PubMed ID: 2427306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of putative dopamine autoreceptor agonists in pharmacological models related to dopaminergic and neuroleptic activity.
    Arnt J; Christensen AV; Hyttel J; Larsen JJ; Svendsen O
    Eur J Pharmacol; 1982 Dec; 86(2):185-98. PubMed ID: 6130958
    [No Abstract]   [Full Text] [Related]  

  • 19. Neuroleptic activity of chiral trans-hexahydro-gamma-carbolines.
    Sarges R; Howard HR; Donahue KM; Welch WM; Dominy BW; Weissman A; Koe BK; Bordner J
    J Med Chem; 1986 Jan; 29(1):8-19. PubMed ID: 3941416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conformational properties of butaclamol and isobutaclamol. Regularities in the structures of semirigid neuroleptics.
    Froimowitz M; Matthysse S
    Mol Pharmacol; 1983 Sep; 24(2):243-50. PubMed ID: 6193405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.